2018
DOI: 10.4103/ijdvl.ijdvl_92_18
|View full text |Cite
|
Sign up to set email alerts
|

Vismodegib treatment in a HIV positive patient on antiretroviral therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
10
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

3
5

Authors

Journals

citations
Cited by 27 publications
(11 citation statements)
references
References 5 publications
0
10
0
1
Order By: Relevance
“…Basal cell carcinoma (BCC) is the most common NMSC. Although surgery is the first-line therapy for BCC, some cases can progress to an advanced or—very rarely—a metastatic state, frequently requiring nonsurgical approaches such as cryotherapy, adjuvant radiotherapy, and targeted therapy [4]. Vismodegib is a Hedgehog pathway inhibitor therapy for patients who are affected by locally advanced BCC or metastatic BCC and who are ineligible for surgery and/or radiotherapy [5].…”
Section: Introductionmentioning
confidence: 99%
“…Basal cell carcinoma (BCC) is the most common NMSC. Although surgery is the first-line therapy for BCC, some cases can progress to an advanced or—very rarely—a metastatic state, frequently requiring nonsurgical approaches such as cryotherapy, adjuvant radiotherapy, and targeted therapy [4]. Vismodegib is a Hedgehog pathway inhibitor therapy for patients who are affected by locally advanced BCC or metastatic BCC and who are ineligible for surgery and/or radiotherapy [5].…”
Section: Introductionmentioning
confidence: 99%
“…
with antiretroviral therapy for HIV infection has been described only once in a patient who received vismodegib together with emtricitabine, rilpivirine and tenofovir [12]. Our case is the first report on successful treatment with sonidegib in co-medication with antiretroviral triple therapy.
…”
mentioning
confidence: 74%
“…In about 6 months of therapy the patient obtained a complete resolution, after which Vismodegib was discontinued. The article reports good tolerance and no interactions between Vismodegib and the previous cART (132). Reports on SHH inhibitors in immunocompromised patients witch locally advanced or metastasizing BCC are rare (133).…”
Section: Target Therapy In Plwhmentioning
confidence: 93%
“…Reports on SHH inhibitors in immunocompromised patients witch locally advanced or metastasizing BCC are rare (133). Effectual use of Vismodegib and the lack of drug to drug interaction with cART (tenofovir/emtricitabine/rilpivirine) has been described in a single case (132). Recently, Hoffmann V. et al have described a successful case of treatment with Sonidegib in a patient on cART.…”
Section: Target Therapy In Plwhmentioning
confidence: 99%